Related Experiment Videos
Carbimazole-induced acute cholestatic hepatitis
G Ozenne1, N D Manchon, J Doucet
1Clinique Thérapeutique, C.H.U. de Rouen, France.
Journal of Clinical Gastroenterology
|February 1, 1989
Summary
Carbimazole, used for hyperthyroidism, can cause cholestatic hepatitis. A patient experienced recurring liver issues upon re-exposure, suggesting an idiosyncratic drug reaction.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Toxicology
Background:
- Hyperthyroidism is commonly treated with antithyroid drugs like carbimazole.
- Drug-induced liver injury (DILI) is a significant concern in clinical practice.
- Cholestatic hepatitis presents a diagnostic challenge, especially in drug-induced cases.
Observation:
- A case of carbimazole-induced cholestatic hepatitis is presented.
- The patient developed cholestasis after 3 months of carbimazole treatment for hyperthyroidism.
- Cholestasis recurred rapidly within 2 days of carbimazole rechallenge.
Findings:
- Histologic examination revealed predominantly centrilobular cholestasis.
- This case adds to the limited literature, with only 5 previously reported instances.
- An idiosyncratic mechanism is proposed for carbimazole-induced cholestatic hepatitis.
Implications:
- Highlights the potential for carbimazole to cause severe cholestatic liver injury.
- Emphasizes the importance of considering drug-induced causes in cholestasis diagnosis.
- Suggests careful monitoring and prompt drug withdrawal if liver injury is suspected.